← boardnext 2027-01next 2027-07next 2028-04-15next 2028-12
BBIO
QED Therapeutics, a BridgeBio companydistress 1/10 · well-funded / low risk$82.270%today-9% from 52w high
Lead: LGMD2I/R9 · target FGFR
Revenue
$195M
Liquidity
$949M
Runway
2.1 yrs
Shares 1y
+3%
Price & events
+2.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
+2.4%
1W
+19.9%
1M
+14.8%
3M
+5.6%
6M
+78.1%
1Y
+199.3%
2Y
+35.8%
5Y
+29.3%
All
Overview
- Market Cap
- $16.11B
- Enterprise Value
- $17.89B
- Volume
- 76.41K
- 52 Week Range
- $44.81 – $90.17
- Total Shares
- 195.86M
- Float Shares
- 164.66M
- Short %
- 13.74%
- % Held by Insiders
- 3.92%
- % Held by Institutions
- 102.05%
- RVOL
- 0.02x
- Beta
- 0.95
Pipeline stages · 4 programs
Infigratinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AG10
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Acoramidis (AG10)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Encaleret
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 10 trials · 9 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01 Estimated 50% readout ~2027-03-17 | Phase 2/3 | infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/daybreakthrough | Hypochondroplasia | — | enrolling by invitation |
| 2027-07 Estimated 50% readout ~2027-08-15 | Phase 2 | AG10 | Amyloid Cardiomyopathy | — | active not recruiting |
| 2028-04-15 Estimated 50% readout ~2028-06-29 | Phase 3 | Acoramidis (AG10) | Amyloid Cardiomyopathy, Transthyretin-Related | — | active not recruiting |
| 2028-12 Estimated 50% readout ~2029-02-14 | Phase 2/3 | Encaleretfast trackorphan | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | — | recruiting |
| 2031-10 Estimated 50% readout ~2031-12-15 | Phase 3 | Acoramidis | Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies | — | recruiting |
Show all 10 trials · 5 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2031-12-01 Estimated 50% readout ~2032-01-15 | Phase 2 | Infigratinibbreakthrough | Achondroplasia | — | enrolling by invitation |
| 2032-03 Estimated 50% readout ~2032-04-15 | Phase 2 | Infigratinib is provided as a single dose of minitablets for oral administration, Infigratbreakthrough | Achondroplasia | — | recruiting |
| 2036-05-31 Estimated 50% readout ~2036-07-15 | Phase 2 | Infigratinibbreakthrough | Hypochondroplasia | — | enrolling by invitation |
| 2037-11 Estimated 50% readout ~2038-01-15 | Phase 3 | Acoramidis (AG10) | Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related, Polyneuropathies, Amyloidosis | — | not yet recruiting |
| 2025-12-18 | Phase 3 | Infigratinib 0.25 mg/kg/daybreakthrough | Achondroplasia | 114 | completed |
Catalyst news & presentations · 24
- between 2027 – 2028Guided 40%trial initiationsecondaryTTR amyloid depleter antibody · program to explore ATTR-CM disease reversalSEC 8-K
- May 8, 2027PDUFAPDUFAencaleret · PDUFA target action date for encaleret NDASEC 8-K
- 2H 2026Guided 55%readoutPhase 2infigratinib · Phase 2 dataSEC 8-K
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)encaleret · MAA submission to EMASEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 3encaleret · Initiate Phase 3 study in chronic hypoparathyroidismSEC 8-K
- November 27, 2026Confirmed 100%PDUFAPDUFABBP-418 · PDUFA target action date for BBP-418 NDA.SEC 8-K
- Q3 2026Guided 70%regulatory submissionFiled (NDA/BLA)infigratinib · Submit NDA to FDASEC 8-K
- later this summertrial initiationsecondaryPhase 3encaleret · Initiate RECLAIM-HP Phase 3 registrational study of encaleretSEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-07-01partnershipCompany sold $933.9M of Series A convertible preferred stock to Sixth Street and HCRx Investments under a new investment agreement.SEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)BBP-418 · Plan to submit NDA for BBP-418SEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)encaleret · NDA submission to FDASEC 8-K
- second half of 2026regulatory submissionFiled (NDA/BLA)oral infigratinib · NDA and MAA submissions plannedSEC 8-K
- May 27, 2026filing acceptanceFiled (NDA/BLA)BBP-418 · FDA accepted NDA for BBP-418 for LGMD2I/R9.SEC 8-K
- May 11, 2026conferencedata presentationsecondaryacoramidis · Late-breaking oral presentation at Heart Failure 2026SEC 8-K
- earlier this monthconferencedata presentationsecondaryPhase 3BBP-418 · Interim Phase 3 FORTIFY data presented at 2026 MDA Clinical and Scientific Conference.SEC 8-K
- end of Q1 2026readoutPhase 3infigratinib · topline results from PROPEL 3SEC 8-K
- Q1 2026trial initiationsecondaryPhase 3encaleret · Initiate registrational trial in pediatric ADH1SEC 8-K
- 2026-03-30regulatory submissionFiled (NDA/BLA)BBP-418 · NDA submitted to FDA for BBP-418.SEC 8-K
- 2026-01-21partnershipRepurchased $82.5M of common stockSEC 8-K
- 2026-01-21partnershipIssued $632.5M 0.75% Convertible Senior Notes due 2033SEC 8-K
- second half 2025readoutPhase 3BBP-418 · Topline readout of interim analysis cohort from FORTIFY trialSEC 8-K
- second half 2025readoutPhase 3encaleret · Topline readout from CALIBRATE trialSEC 8-K
- 2024-09-10trial discontinuedBBP-631 · Company discontinues development due to insufficient investment thresholdSEC 8-K
Approved drugs (1)
- ATTRUBYACORAMIDIS HYDROCHLORIDE2024 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $105 (+28% upside) · 21 analysts
- 2026-07-16CitigroupNeutral
- 2026-07-13HC Wainwright & Co.Buy
- 2026-06-16MizuhoOutperform
- 2026-06-03Canaccord GenuityBuy
- 2026-05-28Morgan StanleyOverweight
- 2026-05-28HC Wainwright & Co.Buy
Competitors — FGFR
- none identified
Recent news
- 2026-07-22BridgeBio Pharma (BBIO) Gains FDA Acceptance for Encaleret in Ra - GuruFocus
- 2026-07-22BridgeBio granted FDA review for hypoparathyroidism therapy - Seeking Alpha
- 2026-07-22BridgeBio (BBIO) Receives FDA Filing Acceptance for New Drug App - GuruFocus
- 2026-07-22FDA accepts BridgeBio’s drug application for rare genetic disorder - Investing.com
- 2026-07-22BridgeBio Pharma Announces FDA Acceptance of NDA for Encaleret in ADH1, Sets PDUFA Date of May 8, 2027 - Quiver Quantitative
- 2026-07-22BridgeBio drug could become first therapy approved specifically for ADH1 - Stock Titan
- 2026-07-17Lobbying Update: $280,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed - Quiver Quantitative
- 2026-07-17Andreas Halvorsen Reduces Stake in BridgeBio Pharma Inc. - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.